Targeted Busulfan therapy with a steady-state concentration of 600-700‚ÄČng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.

Maheshwari S, Kassim A, Yeh RF, Domm J, Calder C, Evans M, Manes B, Bruce K, Brown V, Ho R, Frangoul H, Yang E
Bone Marrow Transplant. 2014 49 (3): 366-9

PMID: 24317124 · DOI:10.1038/bmt.2013.188

MeSH Terms (20)

Adolescent Age Factors Anemia, Sickle Cell Antilymphocyte Serum Bone Marrow Transplantation Busulfan Child Child, Preschool Cyclophosphamide Disease-Free Survival Female Follow-Up Studies HLA Antigens Humans Immunosuppressive Agents Infant Male Neutrophils Siblings Treatment Outcome

Connections (3)

This publication is referenced by other Labnodes entities: